CR Double-Crane(SH:600062) Zheng Quan Zhi Xing·2025-07-27 16:14Core Viewpoint - The legal opinion letter issued by Beijing Zhonglun Law Firm confirms the compliance and authorization of China Resources Double Crane Pharmaceutical Co., Ltd.'s stock repurchase and cancellation plan for part of its restricted stock incentive program [1][2][3] Group 1: Approval and Authorization - The company has obtained necessary approvals and authorizations for the stock repurchase and cancellation, in accordance with relevant regulations and the incentive plan [4][5] - The legal opinion is based on a thorough review of the company's incentive plan and related documents, ensuring compliance with the Company Law and Securities Law [2][3] Group 2: Repurchase Plan Details - The repurchase is due to specific circumstances where certain incentive recipients no longer meet the conditions for holding restricted stock, resulting in a total of 79,013 shares to be repurchased [4][5] - The repurchase price for the shares is set at 6.125 yuan per share for certain recipients and 10.004 yuan per share for others, with adjustments based on market conditions and company performance [6][7] Group 3: Implementation Status - The company has followed the necessary procedures to notify creditors regarding the reduction of registered capital due to the stock repurchase [8] - The repurchase of the shares is expected to be completed by July 30, 2025, with subsequent legal and registration processes to be carried out [8]